Sogroya 5 Mg/1,5 Ml; 10 Mg/1,5 Ml; 15 Mg/1,5 Ml 5 mg, 10 mg; 15 mg Solution for injection
PDF Leaflet Revision Date: 08 October 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Replacement of endogenous growth hormone in GHD patients.
Dosage (summary)
Paediatric: 0.16 mg/kg/week; Adults: 1.5 mg/week (nau00efve), 2 mg/week (women on oestrogen). Elderly: 1 mg/week.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Cytochrome P450 metabolised medicines
- Glucocorticoids
- Antihyperglycaemic medicines
Contraindications
- Hypersensitivity to somapacitan
- Active tumor growth
- Closed epiphyses in children
- Acute critical illness
Common side effects
- Headache
- Hypothyroidism
- Injection site reactions
- Peripheral oedema
- Fatigue
Counselling Points
- Rotate injection sites
- Monitor glucose levels
- Report severe headaches or visual changes
- Adhere to dosing schedule
Serious warnings
- Adrenocortical insufficiency
- Thyroid function monitoring
- Glucose metabolism impairment
- Neoplasms risk
Important Disclaimer
The Sogroya 5 Mg/1,5 Ml; 10 Mg/1,5 Ml; 15 Mg/1,5 Ml 5 mg, 10 mg; 15 mg Solution for injection professional information leaflet below is the property of Novo Nordisk and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
